Emmes’ Post

In this upcoming live broadcast, leading rheumatology and pathology experts discuss why IgG4-related disease should be on your radar and outline steps for diagnosis. Sign up now: https://ow.ly/rvAm50RUiyT #LiveBroadcast #IgG4RD #Rheumatology #Pathology #Radiology 

NASCI 2024 just concluded, showing how the integration of real-world data, including imaging data, is essential for driving innovation in cardiovascular research. Our fit-for-purpose regulatory grade real-world imaging datasets (RWiD) and multimodal longitudinal datasets are tailored to meet the needs of pharmaceutical and biotech companies. These datasets have been instrumental in planning and optimizing clinical trials, ensuring the recruitment of suitable patients. Reach out to us at https://hubs.li/Q02RhfXy0 to know more about how our data sets and solutions have supported identification of suitable patient cohorts for treatment and streamline clinical trial planning. Let’s connect to discover how we can support your next big breakthrough in cardiology. #CardiovascularResearch #MedicalImaging #PharmaExcellence #NASCI2024 #Cardiology #Radiology #RWD #RWiD #RWE

The #tissuediagnostics industry is projected to witness steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.

The #tissuediagnostics industry is projected to witness steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.

The #tissuediagnostics industry is projected to witness steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.

The #tissuediagnostics industry is projected to witness steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.

The #tissuediagnostics industry is projected to witness steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.

🌟 𝐓𝐮𝐞𝐬𝐝𝐚𝐲’𝐬 𝐈𝐧𝐬𝐢𝐠𝐡𝐭: 𝐓𝐡𝐞 𝐓𝐫𝐮𝐞 𝐂𝐨𝐬𝐭 𝐨𝐟 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 Hey everyone, did you know the common figure of $4𝑀 in lost opportunities often quoted in clinical research has its roots way back in 1993? Fast forward to today, and it’s a whole different story. 📊 𝗛𝗲𝗿𝗲’𝘀 𝘄𝗵𝗮𝘁’𝘀 𝗿𝗲𝗮𝗹𝗹𝘆 𝗵𝗮𝗽𝗽𝗲𝗻𝗶𝗻𝗴: Each day a clinical trial runs can mean $500,000 lost in potential sales of drugs or biologics. That’s huge and shows just how impactful our work is in the grand scheme of things. 𝑊ℎ𝑎𝑡 𝑑𝑜𝑒𝑠 𝑖𝑡 𝑐𝑜𝑠𝑡 𝑡𝑜 𝑟𝑢𝑛 𝑎 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑡𝑟𝑖𝑎𝑙? 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈𝐈: $55,716 per day 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈: $23,737 per day 𝐏𝐡𝐚𝐬𝐞 𝐈𝐕: $14,091 per day 𝐏𝐡𝐚𝐬𝐞 𝐈: the least at $7,829 per day 🔬 𝐴𝑟𝑒𝑎𝑠 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑏𝑖𝑔𝑔𝑒𝑠𝑡 𝑡𝑎𝑏𝑠: Think respiratory diseases, immunology, rheumatology, and dermatology. By joining forces at FindMeCure, we’re not just coding or managing data; we're part of a bigger mission to make healthcare faster and more accessible. 👋 𝐿𝑒𝑡’𝑠 𝑀𝑎𝑘𝑒 𝑎 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑇𝑜𝑔𝑒𝑡ℎ𝑒𝑟: We’re here to use our skills to cut down those costs and get vital treatments to patients quicker. 🙌 Huge shoutout to Ken Getz, Tufts University, and Applied Clinical Trials Magazine for the insights. Check out the full article linked in my comments for more info. #ClinicalTrials #HealthTech #SofiaTech #MakingADifference

The #tissuediagnostics industry is projected to witness a steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.

The #tissuediagnostics industry is projected to witness a steady growth with a CAGR of 8.1% during the forecast period of 2023 to 2032 driven by the growing demand for digital pathology.